TMPRSS2 Fluorogenic Assay Kit

Catalog #
$1,205 *
Size: 96 reactions
*US Pricing only. For international pricing, please contact your local distributor.

The TMPRSS2 Fluorogenic Assay is a homogeneous assay that takes advantage of a specific fluorogenic substrate which emits fluorescence upon cleavage by the protease. Only one step is required to assess TMPRSS2 activity: TMPRSS2 protease is incubated with the fluorogenic substrate and fluorescence is measured using a plate reader (λex = 383 nm, λem = 455 nm). Camostat, a known TMPRSS2 inhibitor, is supplied as a protease inhibitor control.

Figure: Illustration of the principle behind the fluorogenic TMPRSS2 protease assay. The peptide substrate is labeled with a fluorophore on one end and an acceptor on the other end. The fluorescence emitted by the donor fluorophore is quenched due to the proximity of the acceptor in the intact peptide. The protease cleaves the peptide and generates a highly fluorescent peptide fragment.

This product has been cited 6 times.

transmembrane protease serine 2 kit, TMPRSS2 assay, TMPRSS2 Fluorescent kit
Product Info
Storage and Usage
Assay Kit Format
Supplied As
The Transmembrane protease, serine 2 (TMPRSS2) Fluorogenic Assay Kit is provided in a 96-well format with purified TMPRSS2, TMPRSS2 Fluorogenic Substrate, and TMPRSS2 assay buffer for 96 reactions.
Materials Required But Not Supplied
  • Fluorescent plate reader capable of reading fluorescence at λex = 383±15 nm, λem = 455±15 nm
  • Adjustable micropipettor and tips
  • Rotating or rocker platform
Catalog # Name Amount Storage
  TMPRSS2* 15 µg -80°C
78047 TMPRSS2 Fluorogenic Substrate (5 mM) 10 µl -20°C (Protect from light)
78048 1x TMPRSS2 Assay Buffer 5 ml -20°C
78049 Camostat 500 µg -80°C
79685 96-well black plate 1 Room Temp

*The concentration of the protein is lot-specific and will be indicated on the tube

UniProt #

TMPRSS2 is a serine protease that facilitates SARS-CoV-2 particle entry into host cells via priming of the viral protein Spike. Its inhibition blocks the fusion of the virus with the plasma membrane after Spike interacts with human receptor Angiotensin-converting enzyme 2 (ACE2), restricting SARS-CoV-2 viral entry, therefore TMPRSS2 is an important therapeutic target for the treatment of COVID-19.

The protein may also play a role in prostate cancer because its gene is frequently altered in tumor cells. Indeed, TMPRSS2-ERG and TMPRSS2-ETV1 fusions are frequent, with TMPRSS2-ERG present in approximately 40 to 80% of human prostate tumors. ETS-related gene (ERG) is a transcription factor that regulates the expression of genes involved in embryonic development, cell proliferation and differentiation, and apoptosis, acting as an oncogene. Alternatively, the tumor suppressor function of TMRSS2 is disrupted since the fusion genes arise from deletions that eliminate the TMPRSS2 coding region while juxtaposing its androgen-inducible promoter and the open reading frame of ERG. Overexpression of ERG contributes to development of androgen-independence in prostate cancer through disruption of androgen receptor signaling.


1. Tomlins, S. A., et al.,2008. "Role of the TMPRSS2-ERG gene fusion in prostate cancer." Neoplasia 10(2): 177-IN9.

2. Hoffmann, M., et al., 2020. “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor”. Cell 181: 271–280.